RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating...
Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma...
– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology...
Study site initiations in the United States for a randomized Phase 2/3 study of CTX-009 with paclitaxel in patients with Biliary...
Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today...
BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel...
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of...
Paper published in the November 2022 issue of Podiatry Management(Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM,...
Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc....
GHO Capital and The Vistria Group to acquire Alcami, a leading high growth CDMO, from Madison Dearborn Partners and Ampersand...
Managing director of the Retinal Degeneration Fund joins board of directorsFORT WORTH, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nacuity...
Conference Call and Webcast at 5:00pm ET on November 14, 2022, Following the Oral PresentationTHE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE...
PGX processing unit to be installed at Agri-Food Discovery Place of University of AlbertaAlginate and yeast beta glucan to be...
Charity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE)...
Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral...
Table: Antiviral Effect of MAU868 vs. Placebo at Week 36 Table: Antiviral Effect of MAU868 vs. Placebo at Week 36New...
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients...
- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis...
Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022...
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase...